MaruX By Fujifilm Biotechnologies Raises The Bar On What's Achievable In Continuous Manufacturing

Continuous manufacturing is redefining expectations for monoclonal antibody production by demonstrating what’s possible when upstream and downstream processes operate as a single, automated system. Recent development data show how sustained perfusion cultures can maintain extremely high cell densities for extended periods, delivering consistent daily titers and strong recovery across connected downstream steps. Compared with traditional fed-batch approaches, this model dramatically compresses timelines, reduces the number of production runs required, and improves overall yield efficiency.

Equally important, product quality remains comparable to — or in some cases improved over — batch processes, highlighting the maturity of modern continuous platforms. These results underscore how long-duration, integrated processing can support both speed and control, without introducing additional risk.

For organizations evaluating next-generation manufacturing strategies, the data offer a clear illustration of how continuous biomanufacturing can raise performance benchmarks across productivity, consistency, and operational efficiency.

Access the full asset to explore the results in detail.